The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MLAB | -28.64% | -74.15% | -23.71% | +2,964% |
| S&P | +10.51% | +83.8% | +12.94% | +1,485% |
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Instruments, Continuous Monitoring, and Biopharmaceutical Development. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Instrument segment designs, manufactures, and markets control instruments and disposable products used in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. The Biopharmaceutical Development segment develops and sells automated systems for protein analysis and peptide synthesis solutions. The Continuous Monitoring segment includes development of systems used to monitor various environmental parameters. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $60.74M | 5.0% |
| Gross Profit | $32.98M | 4.4% |
| Gross Margin | 54.30% | -0.3% |
| Market Cap | $368.65M | -47.5% |
| Market Cap / Employee | $0.51M | 0.0% |
| Employees | 730 | -0.8% |
| Net Income | $2.48M | -27.8% |
| EBITDA | $10.57M | 10.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $20.42M | -16.1% |
| Accounts Receivable | $40.09M | -0.4% |
| Inventory | 27.7 | -6.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $170.16M | 43.5% |
| Short Term Debt | $8.50M | -91.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.36% | 44.7% |
| Return On Invested Capital | -13.55% | -0.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $7.13M | 104.7% |
| Operating Free Cash Flow | $8.22M | 56.0% |
| Metric | Q4 2023 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 598.00 | - | |||
| Price to Book | 4.43 | 4.15 | 3.22 | 2.14 | -50.97% |
| Price to Sales | 3.01 | 2.68 | 2.16 | 1.51 | -51.39% |
| Price to Tangible Book Value | -5.45 | -5.37 | -4.33 | -3.26 | -39.20% |
| Price to Free Cash Flow TTM | 18.11 | 16.51 | 17.20 | 10.89 | -50.45% |
| Enterprise Value to EBITDA | 79.51 | 90.56 | 76.14 | 50.05 | -47.28% |
| Free Cash Flow Yield | 5.5% | 6.1% | 5.8% | 9.2% | 101.80% |
| Return on Equity | -89.4% | -1.3% | -0.4% | -0.9% | -98.97% |
| Total Debt | $211.61M | $193.85M | $184.94M | $178.67M | -19.83% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
